Orchid Pharma Limited — Others, 15-05-2025: Monitoring Agency Report

Orchid Pharma has announced the Monitoring Agency Report on the use of Rs. 400 crore raised via QIP, confirming no deviations from the intended purposes. So far, Rs. 249.24 crore has been utilized—Rs. 44.16 crore on the Jammu manufacturing facility and Rs. 0.36 crore on the new API block at Alathur, both delayed due to land and regulatory issues. Rs. 141 crore went to debt repayment, and Rs. 26.04 crore covered corporate expenses. The remaining Rs. 145.3 crore is parked in fixed deposits earning about 7.6%. Capital expenditure is ongoing with key equipment and construction advancing at Jammu.